CGON Cg Oncology Inc.
Price (delayed)
$22.24
Market cap
$1.7B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.41
Enterprise value
$1.44B
We are a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Our product candidate, cretostimogene, is initially in
Highlights
The quick ratio has soared by 164% YoY
CGON's EPS has soared by 91% YoY and by 74% from the previous quarter
Cg Oncology's net income has shrunk by 81% YoY and by 21% QoQ
Key stats
What are the main financial stats of CGON
Market
Valuations
Earnings
Shares outstanding
76.22M
Market cap
$1.7B
Enterprise value
$1.44B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.05
Price to sales (P/S)
1,220.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,262.72
Revenue
$1.14M
Gross profit
$1.14M
Operating income
-$114.67M
Net income
-$88.04M
EBIT
-$88.04M
EBITDA
-$88.03M
Free cash flow
-$78.95M
Per share
Balance sheet
Liquidity
EPS
-$1.41
EPS diluted
-$1.41
Free cash flow per share
-$1.26
Book value per share
$10.84
Revenue per share
$0.02
TBVPS
$12.08
Total assets
$754.8M
Total liabilities
$21.42M
Debt
$238,000
Equity
$733.38M
Working capital
$732.84M
Debt to equity
0
Current ratio
35.3
Quick ratio
34.76
Net debt/EBITDA
2.92
Margins
Efficiency
Dividend
EBITDA margin
-7,728.6%
Gross margin
100%
Net margin
-7,729.5%
Operating margin
-10,067.3%
Return on assets
-14.4%
Return on equity
-14.7%
Return on invested capital
-17.7%
Return on capital employed
-12%
Return on sales
-7,729.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CGON stock price
How has the Cg Oncology stock price performed over time
Intraday
0.86%
1 week
-16.2%
1 month
-14%
1 year
-45.09%
YTD
-22.45%
QTD
-9.19%
Financial performance
How have Cg Oncology's revenue and profit performed over time
Revenue
$1.14M
Gross profit
$1.14M
Operating income
-$114.67M
Net income
-$88.04M
Gross margin
100%
Net margin
-7,729.5%
The operating income has dropped by 107% year-on-year and by 19% since the previous quarter
Cg Oncology's net income has shrunk by 81% YoY and by 21% QoQ
Cg Oncology's net margin has surged by 68% YoY and by 27% QoQ
CGON's revenue has surged by 67% since the previous quarter
Growth
What is Cg Oncology's growth rate over time
Valuation
What is Cg Oncology stock price valuation
P/E
N/A
P/B
2.05
P/S
1,220.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,262.72
CGON's EPS has soared by 91% YoY and by 74% from the previous quarter
The price to book (P/B) is 50% lower than the last 4 quarters average of 4.1
CGON's equity is up by 37% since the previous quarter
CGON's revenue has surged by 67% since the previous quarter
The stock's P/S is 61% less than its last 4 quarters average of 3086.9
Efficiency
How efficient is Cg Oncology business performance
CGON's ROS has soared by 68% YoY and by 27% from the previous quarter
The company's return on assets has surged by 63% YoY and by 13% QoQ
Cg Oncology's return on invested capital has surged by 57% YoY but it has decreased by 2.9% QoQ
The ROE has increased by 28% since the previous quarter
Dividends
What is CGON's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CGON.
Financial health
How did Cg Oncology financials performed over time
The quick ratio has soared by 164% YoY
Cg Oncology's current ratio has soared by 159% YoY
Cg Oncology's debt is 100% lower than its equity
Cg Oncology's debt has decreased by 48% YoY and by 20% QoQ
CGON's equity is up by 37% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.